Toward new treatments for mantle-cell lymphoma?

New England Journal of Medicine

Volumn 369, Issue 6, 2013, Pages 571-572

  Zucca, Emanuele ^a   Bertoni, Francesco ^a,b  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; BRUTON TYROSINE KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRUTINIB; PREDNISONE; PROTEIN KINASE SYK; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE;

APOPTOSIS; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; ENZYME INHIBITION; HUMAN; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; RECURRENT CANCER; SYK GENE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 84881253102     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1307596     Document Type: Editorial

References (10)

1. Pérez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26-38.
2. Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012;119:1963-71.
3. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009;114:1469-76.
4. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010;107:13075-80.
5. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
6. Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215-23.
7. Staudt LM. II. Therapy of DLBCL based on genomics. Hematol Oncol 2013;31:26-8.
8. Rinaldi A, Kwee I, Taborelli M, et al. Genomic and expression profiling identifies the B cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006;132:303-16. (Pubitemid 43381537)
9. Hadzidimitriou A, Agathangelidis A, Darzentas N, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011;118:3088-95.
10. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-96.